Neuroprotective Effect of Melatonin on Sleep Disorders Associated with Parkinson's Disease

被引：18

作者：

Hu, Xinyu ^{[1
]}

Li, Jingwen ^{[1
]}

Wang, Xinyi ^{[1
]}

Liu, Hanshu ^{[1
]}

Wang, Tao ^{[1
]}

Lin, Zhicheng ^{[2
]}

Xiong, Nian ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan 430022, Peoples R China

[2] Harvard Med Sch, McLean Hosp, Lab Psychiat Neurogenom, Belmont, MA 02478 USA

来源：

ANTIOXIDANTS | 2023年 / 12卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Parkinson's disease; melatonin; sleep disorders; mechanisms; clinical trials; EXCESSIVE DAYTIME SLEEPINESS; RESTLESS LEGS SYNDROME; BEHAVIOR DISORDER; DOUBLE-BLIND; EXOGENOUS MELATONIN; ALPHA-SYNUCLEIN; CONTROLLED-TRIAL; LIGHT THERAPY; MODEL; APNEA;

D O I：

10.3390/antiox12020396

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Parkinson's disease (PD) is a complex, multisystem disorder with both neurologic and systemic manifestations, which is usually associated with non-motor symptoms, including sleep disorders. Such associated sleep disorders are commonly observed as REM sleep behavior disorder, insomnia, sleep-related breathing disorders, excessive daytime sleepiness, restless legs syndrome and periodic limb movements. Melatonin has a wide range of regulatory effects, such as synchronizing circadian rhythm, and is expected to be a potential new circadian treatment of sleep disorders in PD patients. In fact, ongoing clinical trials with melatonin in PD highlight melatonin's therapeutic effects in this disease. Mechanistically, melatonin plays its antioxidant, anti-inflammatory, anti-excitotoxity, anti-synaptic dysfunction and anti-apoptotic activities. In addition, melatonin attenuates the effects of genetic variation in the clock genes of Baml1 and Per1 to restore the circadian rhythm. Together, melatonin exerts various therapeutic effects in PD but their specific mechanisms require further investigations.

引用

页数：23

共 148 条

[41] Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial [J].

Hadi, Fatemeh ;

Agah, Elmira ;

Tavanbakhsh, Samaneh ;

Mirsepassi, Zahra ;

Mousavi, Seyed Vahid ;

Talachi, Negin ;

Tafakhori, Abbas ;

Aghamollaii, Vajiheh .

NEUROLOGICAL SCIENCES, 2022, 43 (10) :6141-6148

[42] POTENTIAL OF MELATONIN REPLACEMENT THERAPY IN OLDER PATIENTS WITH SLEEP DISORDERS [J].

HAIMOV, I ;

LAVIE, P .

DRUGS & AGING, 1995, 7 (02) :75-78

[43] Antioxidative protection by melatonin - Multiplicity of mechanisms from radical detoxification to radical avoidance [J].

Hardeland, R .

ENDOCRINE, 2005, 27 (02) :119-130

[44] Melatonin-A pleiotropic, orchestrating regulator molecule [J].

Hardeland, Ruediger ;

Cardinali, Daniel P. ;

Srinivasan, Venkatramanujam ;

Spence, D. Warren ;

Brown, Gregory M. ;

Pandi-Perumal, Seithikurippu R. .

PROGRESS IN NEUROBIOLOGY, 2011, 93 (03) :350-384

[45] Obstructive Sleep Apnea and Cognition in Parkinson's disease [J].

Harmell, Alexandrea L. ;

Neikrug, Ariel B. ;

Palmer, Barton W. ;

Avanzino, Julie A. ;

Liu, Lianqi ;

Maglione, Jeanne E. ;

Natarajan, Loki ;

Corey-Bloom, Jody ;

Loredo, Jose S. ;

Ancoli-Israel, Sonia .

SLEEP MEDICINE, 2016, 21 :28-34

[46] Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinson's disease [J].

Hidding, U. ;

Gulberti, A. ;

Pflug, C. ;

Choe, C. ;

Horn, A. ;

Prilop, L. ;

Braass, H. ;

Fruendt, O. ;

Buhmann, C. ;

Weiss, D. ;

Westphal, M. ;

Engel, A. K. ;

Gerloff, C. ;

Koppen, J. A. ;

Hamel, W. ;

Moll, C. K. E. ;

Poetter-Nerger, M. .

PARKINSONISM & RELATED DISORDERS, 2019, 62 :141-147

[47]

Högl B, 2002, SLEEP, V25, P905

[48] Activation of nuclear factor κB in obstructive sleep apnea:: a pathway leading to systemic inflammation [J].

Htoo, Aung K. ;

Greenberg, Harly ;

Tongia, Shraddha ;

Chen, Guoqian ;

Henderson, Todd ;

Wilson, David ;

Liu, Shu Fang .

SLEEP AND BREATHING, 2006, 10 (01) :43-50

[49] Parkinson disease with REM sleep behavior disorder Features, α-synuclein, and inflammation [J].

Hu, Yang ;

Yu, Shu-Yang ;

Zuo, Li-Jun ;

Cao, Chen-Jie ;

Wang, Fang ;

Chen, Ze-Jie ;

Du, Yang ;

Lian, Teng-Hong ;

Wang, Ya-Jie ;

Chan, Piu ;

Chen, Sheng-Di ;

Wang, Xiao-Min ;

Zhang, Wei .

NEUROLOGY, 2015, 84 (09) :888-894

[50] Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro [J].

Huang, Jui-Yen ;

Hong, Yu-Ting ;

Chuang, Jih-Ing .

JOURNAL OF NEUROCHEMISTRY, 2009, 109 (05) :1400-1412

← 1 2 3 4 5 6 7 8 9 10 →